Enosi (from Greek ‘enosis’ meaning combination) was formed by Professor Sir Marc Feldmann and Dr. H. Michael Shepard to combine technologies from cancer and autoimmune disease research to create novel and more effective drugs for each disease.
These industry-leading experts will combine their talents, networks and experience to address the growing global health challenges of autoimmune diseases, cancer and acute inflammatory conditions.
Learn about Enosi Life Sciences’ mission, founders, and exciting new scientific research targets for next-generation treatments of cancer and autoimmune diseases.
All TNF blockers and JAK inhibitors have black box warnings related to opportunistic infections, cancer and now cardiovascular events. New drugs with a different mechanism of action are needed to address these problems.
The company is focusing its attention on two projects that are new to treatment of rheumatoid arthritis and other autoimmune disease.
The first project is a specific inhibitor of TNFR1 (EN1001) and the second is a growth factor trap that inactivates inflammatory growth factors which otherwise would induce proliferation of cells that produce TNF in the synovial joints of rheumatoid arthritis patients (EN2001).
Both are new chemical entities that work by novel mechanisms of action and are covered by Enosi’s patent filings. Both programs have precursor molecules with existing in vitro and in vivo proof of concept in animal models of rheumatoid arthritis (RA). EN2001 precursor molecule also has activity in vitro and in vivo in cancer models.
Two other programs are anticipated when funding allows. The first is an anti-TNFR2 program (two products), and the second is an innovative multi-specific antibody-like drug and targeting platform.
Dr. H. Michael Shepard and Professor Sir Marc Feldmann join forces
Director & Co-founder
CEO & Co-founder